• Explore /
  • Poster
  • / A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.

A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.

Abstract Poster

Authors

null

Rebecca Sophie Kristeleit

University College London Cancer Institute, London, United Kingdom

Rebecca Sophie Kristeleit , Nicholas F. Brown , Dagmar Hess , Markus Joerger , Roger Von Moos , Jordi Rodón , Cinta Hierro , Alexa Childs , Anastasios Stathis , Sasa Dimitrijevic , Michael Stumm , Richard Herrmann , Cristiana Sessa , Vincent Bize , Viviane Hess , Andreas Wicki

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Signal Transduction

Clinical Trial Registration Number

NCT01940133

Citation

J Clin Oncol 33, 2015 (suppl; abstr 2592)

DOI

10.1200/jco.2015.33.15_suppl.2592

Abstract #

2592

Poster Bd #

308

Abstract Disclosures

Similar Posters

First Author: A. J. Wagner

First Author: Todd Michael Bauer

First Author: Christian K. Kollmannsberger

First Author: Philippe L. Bedard